Novartis ends Tekturna trial on safety concerns - FiercePharma PDF Print
FiercePharma
The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also at high risk of cardiovascular and renal events after researchers saw an increased number of adverse events--including ...
Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.